Asia Pacific Antibiotics Market By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors), By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others), By Country, Industry Analysis and Forecast, 2020 - 2026

Analysis of Market Size & Trends

The Asia Pacific Antibiotics Market would witness market growth of 6.6% CAGR during the forecast period (2020-2026). The antibacterial agent is another name of antibiotics that has the capability to kill or slow down bacterial growth. It is widely used for curing and preventing diseases caused by bacteria. The increasing number of patients who are suffering from infectious diseases and the evolution of the latest diagnostic devices are some of the major factors that drive the market.

The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases. Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market. On the other hand, advanced prospect molecules and the development of novel combination therapies to cure antibiotic-resistant microbial infections are estimated to propel the market and provide great opportunities for the market players.

With the increasing incidents of infectious diseases, many companies in the market are actively taking efforts for the innovation of advanced products that will propel the growth of the market. There are many infections that become resistant to antibiotics; this situation provides an opportunity for companies to develop advanced products. These advanced products increase the range of treatment by the antibiotics that further support the growth of the market. The innovation of advanced prospect molecules and development of some novel combination therapies which cure antibiotic-resistant infections are expected to support the market growth.

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: Antibiotics Market in Asia Pacific is expected to register a CAGR of 6.6% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Scope of the Study

Market Segments Covered in the Report:

By Action Mechanism

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors,
• Mycolic Acid Inhibitors

By Drug Class

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolides
• Carbapenem
• Aminoglycosides
• Sulfonamides,
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Johnson and Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company